SLC16A1 and pancreatic neoplasm: However, in our selected validation cohort (GSE28735), which contains 45 pancreatic cancer patients with overall survival time, we observed that SLC16A1 and SLC16A3 only demonstrate the same trend if separated the patients into high and low groups at median expression.